We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+10.4%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$3.08B
AUM Growth
+$170M
Cap. Flow
-$43.5M
Cap. Flow %
-1.41%
Top 10 Hldgs %
31.64%
Holding
198
New
2
Increased
42
Reduced
41
Closed
9

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$41.2M
2
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$21.9M
3
UTHR icon
United Therapeutics
UTHR
+$14.5M
4
TMO icon
Thermo Fisher Scientific
TMO
+$12.5M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$11.5M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$21.8M
2
STE icon
Steris
STE
+$20M
3
ILMN icon
Illumina
ILMN
+$18.6M
4
WAT icon
Waters Corp
WAT
+$17.2M
5
BMY icon
Bristol-Myers Squibb
BMY
+$15.4M

Sector Composition

Rank Sector Weight
1 Healthcare 95.67%
2 Real Estate 2.94%
3 Industrials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OHI icon
76
Omega Healthcare
OHI
$15.1B
$11.1M 0.36%
306,433
– –
ARWR icon
77
Arrowhead Research
ARWR
$12.3B
$11M 0.36%
132,886
– –
BPMC
78
DELISTED
Blueprint Medicines
BPMC
$10.8M 0.35%
122,699
– –
BMRN icon
79
BioMarin Pharmaceuticals
BMRN
$11.7B
$10.7M 0.35%
128,004
– –
ZTS icon
80
Zoetis
ZTS
$31.9B
$10.5M 0.34%
56,521
– –
BDX icon
81
Becton Dickinson
BDX
$45.6B
$10.5M 0.34%
44,390
– –
GRTX
82
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$10.2M 0.33%
1,041,845
– –
APLS
83
DELISTED
Apellis Pharmaceuticals
APLS
$9.64M 0.31%
152,538
– –
TBPH icon
84
Theravance Biopharma
TBPH
$873M
$9.53M 0.31%
656,296
+200,000
+44% +$3.76M
NTLA icon
85
Intellia Therapeutics
NTLA
$1.55B
$9.42M 0.31%
58,180
+5,000
+9% +$389K
TPTX
86
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$9.31M 0.3%
119,324
– –
SBRA icon
87
Sabra Healthcare REIT
SBRA
$5.38B
$9.29M 0.3%
510,660
– –
DOC
88
DELISTED
PHYSICIANS REALTY TRUST
DOC
$9.16M 0.3%
495,733
– –
EXEL icon
89
Exelixis
EXEL
$14.1B
$9.1M 0.3%
499,657
-601,263
-55% -$14M
INCY icon
90
Incyte
INCY
$24.9B
$9.06M 0.29%
107,687
– –
UHS icon
91
Universal Health Services
UHS
$9.88B
$8.79M 0.29%
60,023
-11,300
-16% -$1.71M
CTLT
92
DELISTED
CATALENT, INC.
CTLT
$8.65M 0.28%
80,025
– –
REPL icon
93
Replimune Group
REPL
$8.42M 0.27%
219,060
– –
MPT
94
Medical Properties Trust
MPT
$2.81B
$8.28M 0.27%
411,743
– –
ITCI
95
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$8.28M 0.27%
202,756
-29,720
-13% -$1.1M
ACAD icon
96
Acadia Pharmaceuticals
ACAD
$4.55B
$8.09M 0.26%
331,789
– –
BSX icon
97
Boston Scientific
BSX
$68.4B
$7.95M 0.26%
185,931
– –
A icon
98
Agilent Technologies
A
$39.2B
$7.76M 0.25%
52,525
– –
AFMD
99
DELISTED
Affimed
AFMD
$7.72M 0.25%
90,874
+62,072
+216% +$5.66M
ICLR icon
100
Icon
ICLR
$12.8B
$7.51M 0.24%
36,357
+12,765
+54% +$2.75M
2 3
4
5 6

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Tekla Capital Management held 198 positions worth $3.08B, up 5.9% from $2.91B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Tekla Capital Management's Q2 2021 filing shows 2 new, 42 increased, 41 reduced and 9 closed positions. Its largest new stake was VectivBio Holding AG Ordinary Shares: 145,000 shares worth $1.69M. The largest sale was Elevance Health, an estimated $21.8M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q2 2021 buy was VectivBio Holding AG Ordinary Shares: 145,000 shares worth $1.69M.
  • Tekla Capital Management added most to UnitedHealth in Q2 2021, an estimated $41.2M increase.
  • Tekla Capital Management's biggest Q2 2021 reduction was Elevance Health, cutting an estimated $21.8M.
  • Tekla Capital Management fully exited Morphic Holding, Inc. Common Stock in Q2 2021, selling an estimated $5.67M.
  • Tekla Capital Management's ten largest holdings make up 32% of its $3.08B portfolio in Q2 2021.
  • Tekla Capital Management opened 2 new positions and closed 9 in Q2 2021.
  • Tekla Capital Management's portfolio value rose 5.9% quarter-over-quarter to $3.08B.

Based on Tekla Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.